Literature DB >> 7304654

Treatment of Clostridium difficile colitis and diarrhea with vancomycin.

J Silva, D H Batts, R Fekety, J F Plouffe, G D Rifkin, I Baird.   

Abstract

Toxigenic Clostridium difficle is the major cause of antibiotic-associated colitis and is susceptible to vancomycin at fecal concentrations achieved with oral therapy. The effect of oral vancomycin was studied in 16 patients with C. difficile-related diarrhea or colitis, 12 of whom had colitis documented by endoscopy, biopsy, and/or barium enema. Four patients had antibiotic-associated diarrhea and possibly antibiotic-associated colitis, because sigmoidoscopy either showed normal results (two patients) or was not performed (two patients). Nineteen episodes of diarrhea were treated with oral vancomycin in two dosage regimens for three to 14 days. Twelve patients received 2 g daily, and four patients initially received 1 g or less per day. Within 48 hours of the start of vancomycin therapy, 14 of 16 patients (87 percent) showed a decrease in temperature, abdominal pain and diarrhea. Diarrhea ceased completely within two days of the start of vancomycin in nine episodes, within three to seven days in six episodes, and within eight to 14 days in the remaining four episodes, and within eight to 14 days in the remaining four episodes. Diarrhea recurred in two of these patients (12 percent) when the drug inciting the initial episode of colitis was given again 42 days or more after vancomycin therapy was stopped; both patients responded again to retreatment with vancomycin. Oral vancomycin is an effective treatment of C. difficile-related colitis and diarrhea.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7304654     DOI: 10.1016/0002-9343(81)90369-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  In vitro synergy studies with Clostridium difficile.

Authors:  A E Bacon; S McGrath; R Fekety; W J Holloway
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Update on pseudomembranous colitis.

Authors:  J Silva
Journal:  West J Med       Date:  1989-12

3.  Antibiotic-associated colitis.

Authors:  J Silva
Journal:  West J Med       Date:  1984-02

4.  An agent-based simulation model for Clostridium difficile infection control.

Authors:  James Codella; Nasia Safdar; Rick Heffernan; Oguzhan Alagoz
Journal:  Med Decis Making       Date:  2014-08-11       Impact factor: 2.583

Review 5.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 6.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

7.  Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine.

Authors:  A Pantosti; I Luzzi; R Cardines; P Gianfrilli
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

8.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Treatment of Clostridium difficile-associated disease with teicoplanin.

Authors:  F de Lalla; G Privitera; E Rinaldi; G Ortisi; D Santoro; G Rizzardini
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

10.  Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile.

Authors:  S Cronberg; B Castor; A Thorén
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.